IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $43.36 Average PT from Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has earned an average recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $44.1333.

IDYA has been the subject of a number of research reports. Citigroup reiterated a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. BTIG Research reiterated a “buy” rating and issued a $62.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, October 21st. Guggenheim initiated coverage on IDEAYA Biosciences in a report on Thursday, September 18th. They set a “buy” rating and a $50.00 price target for the company. Stephens restated an “overweight” rating and set a $45.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, New Street Research set a $30.00 price target on IDEAYA Biosciences in a report on Tuesday.

Institutional Investors Weigh In On IDEAYA Biosciences

Large investors have recently bought and sold shares of the business. CWM LLC increased its holdings in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after buying an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after buying an additional 1,546 shares in the last quarter. Signaturefd LLC increased its holdings in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after buying an additional 2,271 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in IDEAYA Biosciences in the 2nd quarter worth about $61,000. Finally, Daiwa Securities Group Inc. increased its holdings in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Stock Up 2.7%

Shares of IDYA stock opened at $29.18 on Friday. The stock has a fifty day moving average of $26.20 and a 200 day moving average of $22.70. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $32.67. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -7.70 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million during the quarter, compared to analyst estimates of $3.48 million. The company’s quarterly revenue was up NaN% compared to the same quarter last year. During the same period last year, the business posted ($0.68) EPS. Equities research analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.